AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Risankizumab for Ulcerative Colitis
JAMA Author Interviews
Study on Risankizumab for Ulcerative Colitis
The chapter summarizes the results of a phase 3 trial on Risankizumab for ulcerative colitis, showing higher rates of clinical remission in patients receiving the drug compared to placebo during the induction study, and sustained remission at 52 weeks with fewer adverse events in the maintenance study.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode